Amylyx Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -98 | -108 | -19,855 | |
EBITDA | -43,380 | -41,186 | -30,949 | -34,266 |
EBIT | -43,423 | -41,284 | -31,057 | -34,386 |
Net Income | -43,423 | -41,284 | -32,999 | -34,386 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -31,454 | -36,882 | -27,989 | -30,392 |
Cash | 49,326 | 229,136 | 226,651 | 225,178 |
Basic Shares | 111,196 | 110,563 | 94,565 | 93,332 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $87,371 | $380,786 | $22,230 |
Gross Profit | -525 | 45,215 | 355,345 | 19,237 |
EBITDA | -144,164 | -290,976 | 55,385 | -200,854 |
EBIT | -144,689 | -291,880 | 54,297 | -201,341 |
Net Income | -144,735 | -301,743 | 49,271 | -198,375 |
Net Change In Cash | 0 | 87,371 | 380,786 | 22,230 |
Cost of Revenue | 12,930 | |||
Free Cash Flow | -123,481 | -167,804 | 10,678 | -182,397 |
Cash | 226,651 | 77,391 | 170,201 | 62,526 |
Basic Shares | 94,565 | 68,142 | 69,991 | 66,512 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.39 |
2026-03-31 | -$0.37 |
2025-12-31 | -$0.30 |
2025-09-30 | -$0.37 |